CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21698

CHEMISTRY REVIEW(S)

NDA 21-698

Over The Counter ZANTAC 150

Pfizer Consumer Healthcare/
Division of Warner-Lambert & Co.,LLC

Ramesh Raghavachari, Ph.D.
DNDC II, Office of New Drug Chemistry
for
Division of Gastrointestinal and Coagulation Drug Products
HFD-180

Table of Contents

Chemistry Review Data Sheet

1. NDA # 21-698

2. REVIEW # 1

3. REVIEW DATE: June 30, 2004.

4. REVIEWER: Ramesh Raghavachari, Ph.D.

5. PREVIOUS DOCUMENTS:

Previous Documents	Document Date
None	

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed	Document Date
Original	October 31, 2003
BC	February 23, 2004
BC	April 14, 2004
BL	May 06, 2004

7. NAME & ADDRESS OF APPLICANT:

Name:	Pfizer Inc.
Address:	201 Tabor Road, Morris Plains, NJ 07950
Representative:	John R. Jacobs
Telephone:	973-385-5419

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: Over –the –Counter Zantac 150 ™
b) Non-Proprietary Name (USAN): Ranitidine Hydrochloride
c) Code Name/# (ONDC only): N/A
d) Chem. Type/Submission Priority (ONDC only):

- Chem. Type: 8 *(based on the latest draft MAPP dated April 18, 2003 of the CDER Office of New Drugs, Drug and Application Classification)*
- Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: This application was filed under the provisions of section 505(b)(1) of Federal Food Drug and Cosmetic Act and 21 CFR 314.50

10. PHARMACOL. CATEGORY: Histamine H2 receptor inhibitor

11. DOSAGE FORM: Tablets

12. STRENGTH/POTENCY: 150 mg

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
_____SPOTS product – Form Completed

___X___Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:



Ranitidine. HCl

N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1- ethenediamine, HCl.

Molecular Formula: $C_{13}H_{22}N_4O_3S \cdot HCl$
Molecular Weight : 350.87

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE[1]	STATUS[2]	DATE REVIEW COMPLETED	COMMENTS
				4	Adequate	N/A	Data provided in the application.
	III			3	Adequate	Sept. 15, 2000	
	III			3	Adequate	April 22, 2002	
	III			7	Adequate	Not reviewed	Low risk /ONDC policy referred.
	III			3	Adequate	Dec. 7, 2000	
	III			1	Adequate	Sep. 27, 2000	Reviewed by DMF strike force
	III			1	Adequate	Sep. 27, 2000	Reviewed by DMF strike force
	III			3	Adequate	Feb. 25, 2004	

Chemistry Review Data Sheet

OGD: N/A

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Microbiology			
EES			
Methods Validation			
Labeling			
Bioequivalence			
EA			
Radiopharmaceutical			

19. ORDER OF REVIEW (OGD Only): N/A

The application submission(s) covered by this review was taken in the date order of receipt. ____ Yes ____ No If no, explain reason(s) below:

APPEARS THIS WAY
ON ORIGINAL

The Chemistry Review for NDA 21-698

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From the Chemistry, Manufacturing and Controls (CMC) point of view, NDA-21-698 is recommended for approval.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

Not applicable. [This is an approved drug that has been marketed as a prescription drug for over 20 years and the 75 mg dose for Zantac has been over-the-counter for over eight years.]

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

The drug substance and drug product have been approved under NDAs 18-703 and 20-520. This application is to market the prescription Zantac 150 mg tablets over-the-counter. The drug substance is manufactured in [redacted]. The drug product is manufactured and [redacted]. The drug product is packaged in three different configurations- [redacted] bottles, [redacted] blisters and [redacted] pouches in the original application. During review it was determined that stability data for the 150 mg Zantac in [redacted] ottles has been provided and no stability data on the [redacted] lister and [redacted] pouch was included in the submission. However, supporting data for the above two packaging configurations using the 75 mg Zantac was included. This was identified as a filing issue and communicated to the applicant. Applicant then amended the application (April 14, 2004) [redacted] and providing additional stability data for the [redacted] olister packaging. All three packaging configurations have been approved for the Zantac 75 mg over-the-counter product in 1995. The applicant also submitted an amendment to draft labeling and packaging insert to the agency dated May 06, 2004.

B. Description of How the Drug Product is Intended to be Used

The drug is for over-the-counter use. It is recommended [redacted] to relieve the symptoms of heartburn associated with acid indigestion and sour stomach. The labeling [redacted] not more than two tablets be taken over a period of 24 hours.

C. Basis for Approvability or Not-Approval Recommendation

The drug product is approved under NDA 18-703 for dispensing by prescription and the Zantac 75 mg strength has been approved under 20-520 for over-the-counter dispensing. The drug substance specifications, formulation and the drug product specifications have not changed from the NDA 18-703 application. Only the [redacted] on the drug product of Zantac 150 mg Over-the-counter has slightly changed to [redacted] and all approved ingredients have been used. This drug product has a track record for over twenty years. It is anticipated, that this drug would not have any serious risks to public health.

The applicant has requested 24 month expiry dating period. The stability data provided by the applicant is adequate for assigning 24 month expiry dating for the [redacted] bottle packaging and the blister packaging configurations.

III. Administrative

A. Reviewer's Signature

Signed electronically in DFS by Ramesh Raghavachari, Ph.D. Review Chemist, HFD-180

B. Endorsement Block

Signed electronically in DFS by Liang Zhou, Ph.D. Chemistry Team Leader, HFD-180

Ramesh Raghavachari, Ph.D. /Date: July 6, 2004
Liang Zhou, Ph.D. /Date:
Diane Moore /Date

C. CC Block

NDA 21-698
HFD-180/Chemistry Reviewer/rraghavachari
HFD-180/Chemistry Team Leader/lzhou
HFD-820/Director/Deputy Director/eduffy/bfraser
HFD-180/Project Manager/dmoore
HFD-180/Div. File/NDA 21-698

38 Page(s) Withheld

✓ Trade Secret / Confidential

_____ Draft Labeling

_____ Deliberative Process

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Ramesh Raghavachari
7/6/04 03:14:23 PM
CHEMIST
There is no IR letter or DR letter required for the CMC section.

Liang Zhou
7/6/04 03:47:43 PM
CHEMIST